Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06021054 · ClinicalTrials.gov registry record · Phase 3
An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2)
A Phase 3 study, sponsored by Viridian Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 188
- Enrollment target
NCT06021054 is a Phase 3 study that has completed, run by Viridian Therapeutics. The registered enrollment target is 188 participants.
The verdict
NCT06021054, a Phase 3 study, has completed, sponsored by Viridian Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 188 participants
- Enrollment target
Study Summary
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, veligrotug (VRDN-001), in participants with chronic thyroid eye disease (TED).
Interventions
- DRUG Placebo
- DRUG Veligrotug (VRDN-001)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2023-11-14 |
| Est. Completion | 2025-07-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06021054
The ClinicalTrials.gov registry entry for NCT06021054 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 188 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Viridian Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06021054 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06021054 about?
NCT06021054 is a clinical study titled "An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2)". This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, veligrotug (VRDN-001), in participants with chronic thyroid eye disease (TED).
What is the current status of trial NCT06021054?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 188 participants. The study started on 2023-11-14. Estimated completion is 2025-07-25.
What interventions are being tested in trial NCT06021054?
The interventions under investigation include: Placebo (DRUG), Veligrotug (VRDN-001) (DRUG).
Who is sponsoring clinical trial NCT06021054?
This trial is sponsored by Viridian Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.